Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes

PURPOSE: Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1 diabetes (T1D). Sotagliflozin may meet this need, because this compound lowers blood glucose through the insulin-independent mechanisms of inhibiting kidney SGLT2 and intestin...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes Metab Syndr Obes
Main Authors: Powell, David R, Doree, Deon, Jeter-Jones, Sabrina, Ding, Zhi-Ming, Zambrowicz, Brian, Sands, Arthur
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2015
Subjects:
Original Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4346285/
https://ncbi.nlm.nih.gov/pubmed/25759591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S76342
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items